Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

被引：255

作者：

Apetoh, L. ^{[1
,2
,3
]}

Ladoire, S. ^{[1
,2
,3
]}

Coukos, G. ^{[4
]}

Ghiringhelli, F. ^{[1
,2
,3
]}

机构：

[1] INSERM, U866, Lipids Nutr Canc, Dijon, France

[2] Univ Bourgogne, Dept Med, Dijon, France

[3] Ctr Georges Francois Leclerc, Dept Oncol, Dijon, France

[4] Univ Lausanne, Dept Oncol, Lausanne, Switzerland

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷 / 09期

关键词：

chemotherapy; radiotherapy; anticancer immunity; immunomodulation; CD4 T cells; CD8 T cells; REGULATORY T-CELLS; METASTATIC BREAST-CARCINOMA; C-RECEPTOR POLYMORPHISMS; VIVO ANTITUMOR-ACTIVITY; NATURAL-KILLER-CELLS; DE-NOVO MALIGNANCY; TUMOR-CELLS; IN-VIVO; ADOPTIVE IMMUNOTHERAPY; SUPPRESSOR-CELLS;

D O I：

10.1093/annonc/mdv209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Recent clinical trials revealed the impressive efficacy of immunological checkpoint blockade in different types of metastatic cancers. Such data underscore that immunotherapy is one of the most promising strategies for cancer treatment. In addition, preclinical studies provide evidence that some cytotoxic drugs have the ability to stimulate the immune system, resulting in anti-tumor immune responses that contribute to clinical efficacy of these agents. These observations raise the hypothesis that the next step for cancer treatment is the combination of cytotoxic agents and immunotherapies. The present review aims to summarize the immune-mediated effects of chemotherapeutic agents and their clinical relevance, the biological and clinical features of immune checkpoint blockers and finally, the preclinical and clinical rationale for novel therapeutic strategies combining anticancer agents and immune checkpoint blockers.

引用

页码：1813 / 1823

页数：11

共 166 条

[1]

A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients [J].

Adotevi, Olivier ;

Pere, Helene ;

Ravel, Patrice ;

Haicheur, Nacilla ;

Badoual, Cecile ;

Merillon, Nathalie ;

Medioni, Jacques ;

Peyrard, Severine ;

Roncelin, Stephane ;

Verkarre, Virginie ;

Mejean, Arnaud ;

Fridman, Wolf H. ;

Oudard, Stephane ;

Tartour, Eric .

JOURNAL OF IMMUNOTHERAPY, 2010, 33 (09) :991-998

[2]

THE YIN AND YANG OF T-CELL COSTIMULATION [J].

ALLISON, JP ;

KRUMMEL, MF .

SCIENCE, 1995, 270 (5238) :932-933

[3]

Amin A, 2014, ESMO 2014 2014

[4]

Cancer treatment: the combination of vaccination with other therapies [J].

Andersen, Mads Hald ;

Sorensen, Rikke Baek ;

Schrama, David ;

Svane, Inge Marie ;

Becker, Juergen C. ;

Straten, Per thor .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (11) :1735-1743

[5]

[Anonymous], CANC RES S

[6]

[Anonymous], J NATL CANC I

[7]

[Anonymous], 2013, Oncoimmunology, DOI DOI 10.4161/ONCI.25595

[8]

[Anonymous], BIOMED J

[9]

Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies [J].

Apetoh, L. ;

Vegran, F. ;

Ladoire, S. ;

Ghiringhelli, F. .

CURRENT MOLECULAR MEDICINE, 2011, 11 (05) :365-372

[10]

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

← 1 2 3 4 5 6 7 8 9 10 →